How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease
暂无分享,去创建一个
[1] Ravy K. Vajravelu,et al. Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease , 2018, Journal of Crohn's & colitis.
[2] W. Sandborn,et al. High body mass index is associated with increased risk of treatment failure and surgery in biologic‐treated patients with ulcerative colitis , 2018, Alimentary pharmacology & therapeutics.
[3] S. Shen-Orr,et al. Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD , 2018, Gut.
[4] D. Franchimont,et al. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. , 2018, Gastroenterology.
[5] S. Vermeire,et al. Immunogenicity of biologics in inflammatory bowel disease , 2018, Therapeutic advances in gastroenterology.
[6] Ravy K. Vajravelu,et al. Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease , 2018, Digestive Diseases and Sciences.
[7] D. Hommes,et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial , 2017, The Lancet.
[8] A. Ford,et al. Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease , 2017, Inflammatory bowel diseases.
[9] S. Vermeire,et al. Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease , 2017, Alimentary pharmacology & therapeutics.
[10] Ravy K. Vajravelu,et al. Improved Long‐term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[11] S. Shahrokh,et al. Transmembrane TNF-α Density, but not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease , 2017, Clinical and Translational Gastroenterology.
[12] R. Arsenescu,et al. Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease , 2017, Inflammatory bowel diseases.
[13] M. Silverberg,et al. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease , 2017, Inflammatory bowel diseases.
[14] M. Abreu,et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease , 2017, Alimentary pharmacology & therapeutics.
[15] D. Mould,et al. A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease , 2017, Inflammatory bowel diseases.
[16] C. Ponsioen,et al. Suppression of anti‐drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease , 2017, Alimentary pharmacology & therapeutics.
[17] D. Laukens,et al. Review article: dose optimisation of infliximab for acute severe ulcerative colitis , 2017, Alimentary pharmacology & therapeutics.
[18] Konstantinos Papamichael,et al. Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF Therapy , 2017, The American Journal of Gastroenterology.
[19] C. Selinger,et al. Medication non-adherence in adult patients affected by inflammatory bowel disease: a critical review and update of the determining factors, consequences and possible interventions , 2017, Expert review of gastroenterology & hepatology.
[20] G. Kaplan,et al. Systematic review with meta‐analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis , 2017, Alimentary pharmacology & therapeutics.
[21] R. Eliakim,et al. Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn’s Disease , 2016, Journal of Crohn's & colitis.
[22] A. Gonçalves,et al. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point‐of‐care quantitative test with two established ELISA assays , 2016, Alimentary pharmacology & therapeutics.
[23] M. Dubinsky,et al. Therapeutic drug monitoring in inflammatory bowel disease , 2016, Current opinion in pediatrics.
[24] R. Xavier,et al. Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn’s Disease , 2016, The American Journal of Gastroenterology.
[25] S. Vermeire,et al. A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease , 2016, The American Journal of Gastroenterology.
[26] V. Annese,et al. Circulating T cells to infliximab are detectable mainly in treated patients developing anti‐drug antibodies and hypersensitivity reactions , 2016, Clinical and experimental immunology.
[27] P. Rutgeerts,et al. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies , 2016, Journal of Crohn's & colitis.
[28] U. Vogel,et al. Systematic review: genetic biomarkers associated with anti‐TNF treatment response in inflammatory bowel diseases , 2016, Alimentary pharmacology & therapeutics.
[29] F. Aubin,et al. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview , 2016, RMD Open.
[30] U. Kopylov,et al. Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis , 2016, Alimentary pharmacology & therapeutics.
[31] R. Baldassano,et al. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease , 2016, Inflammatory bowel diseases.
[32] R. Eliakim,et al. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[33] M. V. van Oijen,et al. Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study. , 2016, Journal of Crohn's & colitis.
[34] N. Ding,et al. Systematic review: predicting and optimising response to anti‐TNF therapy in Crohn's disease – algorithm for practical management , 2016, Alimentary pharmacology & therapeutics.
[35] P. Rutgeerts,et al. Anti–Tumor Necrosis Factor Therapy Restores Peripheral Blood B-cell Subsets and CD40 Expression in Inflammatory Bowel Diseases , 2015, Inflammatory bowel diseases.
[36] P. Rutgeerts,et al. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease. , 2015, Gastroenterology.
[37] K. Van Steen,et al. Restoration of Foxp3+ Regulatory T-cell Subsets and Foxp3− Type 1 Regulatory-like T Cells in Inflammatory Bowel Diseases During Anti-tumor Necrosis Factor Therapy , 2015, Inflammatory bowel diseases.
[38] Biao Wang,et al. A Note on an Improved Self-Healing Group Key Distribution Scheme , 2015, Sensors.
[39] C. Ponsioen,et al. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. , 2015, Gastroenterology.
[40] L. Peyrin-Biroulet,et al. Cumulative Incidence of, Risk Factors for, and Outcome of Dermatological Complications of Anti-TNF Therapy in Inflammatory Bowel Disease: A 14-Year Experience , 2015, The American Journal of Gastroenterology.
[41] L. Peyrin-Biroulet,et al. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease. , 2015, Journal of Crohn's & colitis.
[42] G. D'Haens,et al. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease , 2015, Scandinavian journal of gastroenterology.
[43] L. Öhman,et al. Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy , 2015, Scandinavian journal of gastroenterology.
[44] M. J. Kim,et al. Infliximab “Top-Down” Strategy is Superior to “Step-Up” in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease , 2015, Journal of pediatric gastroenterology and nutrition.
[45] L. Öhman,et al. Cultured blood T‐cell responses predict anti‐TNF therapy response in patients with ulcerative colitis , 2015, Alimentary pharmacology & therapeutics.
[46] K. Van Steen,et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. , 2015, Gastroenterology.
[47] E. Zoetendal,et al. Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation , 2015, The American Journal of Gastroenterology.
[48] A. Bitton,et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. , 2015, Gastroenterology.
[49] S. Vermeire,et al. Immunogenicity to infliximab is associated with HLA-DRB1 , 2015, Gut.
[50] K. Bendtzen. Immunogenicity of Anti-TNF-α Biotherapies: II. Clinical Relevance of Methods Used for Anti-Drug Antibody Detection , 2015, Front. Immunol..
[51] R. Eliakim,et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[52] A. Pérez‐Pitarch,et al. A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients. , 2015, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.
[53] M. Bechtold,et al. pANCA Positivity Predicts Lower Clinical Response to Infliximab Therapy among Patients with IBD , 2015, Southern medical journal.
[54] J. Barkin,et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study , 2015, Gut.
[55] Sumant Inamdar,et al. Smoking and early infliximab response in Crohn’s disease: a meta-analysis. , 2015, Journal of Crohn's & colitis.
[56] B. Flourié,et al. Accuracies of Serum and Fecal S100 Proteins (Calprotectin and Calgranulin C) to Predict the Response to TNF Antagonists in Patients with Crohn's Disease , 2015, Inflammatory bowel diseases.
[57] B. Burnand,et al. Factors Associated with Durable Response to Infliximab in Crohn's Disease 5 Years and Beyond: A Multicenter International Cohort , 2015, Inflammatory bowel diseases.
[58] M. Silverberg,et al. Serological markers associated with disease behavior and response to anti‐tumor necrosis factor therapy in ulcerative colitis , 2015, Journal of gastroenterology and hepatology.
[59] D. Mould,et al. Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study , 2014, Inflammatory bowel diseases.
[60] P. Rutgeerts,et al. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis , 2014, Alimentary pharmacology & therapeutics.
[61] L. Guidi,et al. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. , 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[62] L. Aarden,et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region , 2014, Annals of the rheumatic diseases.
[63] G. Greenberg,et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease , 2014, Gut.
[64] M. Dubinsky,et al. Early Infliximab Trough Levels Are Associated with Persistent Remission in Pediatric Patients with Inflammatory Bowel Disease , 2014, Inflammatory bowel diseases.
[65] A. Griffiths,et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. , 2014, Journal of Crohn's & colitis.
[66] U. Kopylov,et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease , 2014, Alimentary pharmacology & therapeutics.
[67] P. Rutgeerts,et al. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[68] Merel E Hellemons,et al. Adalimumab for Crohn's disease: long-term sustained benefit in a population-based cohort of 438 patients. , 2014, Journal of Crohn's & colitis.
[69] S. Saini,et al. Systematic review with network meta‐analysis: the efficacy of anti‐TNF agents for the treatment of Crohn's disease , 2014, Alimentary pharmacology & therapeutics.
[70] M. Frydenberg,et al. Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease , 2014, The Pharmacogenomics Journal.
[71] Markus F. Neurath,et al. Cytokines in inflammatory bowel disease , 2014, Nature Reviews Immunology.
[72] S. Saini,et al. Systematic review with network meta‐analysis: the efficacy of anti‐tumour necrosis factor‐alpha agents for the treatment of ulcerative colitis , 2014, Alimentary pharmacology & therapeutics.
[73] G. Pasut. Pegylation of Biological Molecules and Potential Benefits: Pharmacological Properties of Certolizumab Pegol , 2014, BioDrugs.
[74] O. Dewit,et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[75] T. Macdonald,et al. Proteases and small intestinal barrier function in health and disease , 2014, Current opinion in gastroenterology.
[76] Wolfgang Uter,et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease , 2014, Nature Medicine.
[77] P. Rutgeerts,et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial , 2014, Gut.
[78] G. Corazza,et al. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn’s disease , 2013, The European Journal of Health Economics.
[79] Graham M Lord,et al. The challenges of stratifying patients for trials in inflammatory bowel disease. , 2013, Trends in immunology.
[80] M. Lukáš,et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. , 2013, Journal of Crohn's & colitis.
[81] U. Kopylov,et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab , 2013, Gut.
[82] J. Mclaughlin,et al. Modifiable Factors Associated with Nonadherence to Maintenance Medication for Inflammatory Bowel Disease , 2013, Inflammatory bowel diseases.
[83] D. Caldeira,et al. Infliximab Reduces Hospitalizations and Surgery Interventions in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis , 2013, Inflammatory bowel diseases.
[84] M. Sinanan,et al. Increased Body Mass Index Is Associated with Earlier Time to Loss of Response to Infliximab in Patients with Inflammatory Bowel Disease , 2013, Inflammatory bowel diseases.
[85] L. A. Christensen,et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial , 2013, Gut.
[86] H. Tanke,et al. A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study , 2013, Analytical and Bioanalytical Chemistry.
[87] L. Peyrin-Biroulet,et al. Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases: A Systematic Review , 2013, Inflammatory Bowel Diseases.
[88] P. Rutgeerts,et al. Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient , 2013, The American Journal of Gastroenterology.
[89] K. Bendtzen,et al. Pre‐existing IgG antibodies cross‐reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease , 2013, Alimentary pharmacology & therapeutics.
[90] S. Brand,et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment , 2013, Gut.
[91] Guilherme Macedo,et al. High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment. , 2013, Journal of Crohn's & colitis.
[92] L. Biancone,et al. Distinct Profiles of Effector Cytokines Mark the Different Phases of Crohn’s Disease , 2013, PloS one.
[93] J. Gisbert,et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response , 2012, Inflammatory bowel diseases.
[94] G. Greenberg,et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. , 2012, The New England journal of medicine.
[95] David C. Wilson,et al. Management of Pediatric Ulcerative Colitis: Joint ECCO and ESPGHAN Evidence-based Consensus Guidelines , 2012, Journal of pediatric gastroenterology and nutrition.
[96] L. Biancone,et al. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study , 2012, Alimentary pharmacology & therapeutics.
[97] M. Nurmohamed,et al. IgG4 Production Against Adalimumab During Long Term Treatment of RA Patients , 2012, Journal of Clinical Immunology.
[98] R. Fossmark,et al. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease , 2012, Scandinavian journal of gastroenterology.
[99] Michael Vieth,et al. Confocal Laser Endomicroscopy , 2012, Gastroenterology research and practice.
[100] Rasmus Goll,et al. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis , 2012, Scandinavian journal of gastroenterology.
[101] B. Meibohm,et al. Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy , 2012, The AAPS Journal.
[102] G. Corazza,et al. New Pathogenic Paradigms in Inflammatory Bowel Disease , 2012, Inflammatory bowel diseases.
[103] L. Aarden,et al. Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. , 2012, Journal of immunological methods.
[104] A. Barton,et al. Genetic and genomic predictors of anti-TNF response. , 2011, Pharmacogenomics.
[105] P. Rutgeerts,et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. , 2011, Gastroenterology.
[106] G. Veres,et al. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease , 2011, Alimentary pharmacology & therapeutics.
[107] P. Rutgeerts,et al. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[108] Honghui Zhou,et al. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. , 2011, Clinical therapeutics.
[109] J. Kelsen,et al. Infliximab Therapy in Pediatric Patients 7 Years of Age and Younger , 2014, Journal of pediatric gastroenterology and nutrition.
[110] S. Ben-Horin,et al. Review article: loss of response to anti‐TNF treatments in Crohn’s disease , 2011, Alimentary pharmacology & therapeutics.
[111] Martin Schiestl,et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals , 2011, Nature Biotechnology.
[112] L. Peyrin-Biroulet,et al. Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review , 2011, The American Journal of Gastroenterology.
[113] B. Flourié,et al. A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization , 2010, The American Journal of Gastroenterology.
[114] Kristel Van Steen,et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease‡ , 2010, Inflammatory bowel diseases.
[115] G. Corazza,et al. Peripheral regulatory T cells and serum transforming growth factor‐&bgr;: Relationship with clinical response to infliximab in Crohn's disease , 2010, Inflammatory bowel diseases.
[116] P. Rutgeerts,et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.
[117] S. Benoit,et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. , 2010, Arthritis and rheumatism.
[118] G Van Assche,et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis , 2009, Gut.
[119] G. Cui,et al. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. , 2009, Cytokine.
[120] C. Lees,et al. The safety profile of anti‐tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient‐years follow‐up , 2009, Alimentary pharmacology & therapeutics.
[121] J. Gisbert,et al. Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review , 2009, The American Journal of Gastroenterology.
[122] W Wang,et al. Monoclonal Antibody Pharmacokinetics and Pharmacodynamics , 2008, Clinical pharmacology and therapeutics.
[123] P. Rutgeerts,et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. , 2008, Gastroenterology.
[124] M. H. Ryan,et al. Human Anti-IgG1 Hinge Autoantibodies Reconstitute the Effector Functions of Proteolytically Inactivated IgGs1 , 2008, The Journal of Immunology.
[125] P. Tak,et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. , 2008, Pharmacology & therapeutics.
[126] S. Akilesh,et al. FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.
[127] A. Levine,et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease , 2007, Gut.
[128] S. Schreiber,et al. Certolizumab pegol for the treatment of Crohn's disease. , 2007, The New England journal of medicine.
[129] S. Schreiber,et al. Maintenance therapy with certolizumab pegol for Crohn's disease. , 2007, The New England journal of medicine.
[130] P. Rutgeerts,et al. Predictive Model for the Outcome of Infliximab Therapy in Crohn's Disease Based on Apoptotic Pharmacogenetic Index and Clinical Predictors , 2007, Inflammatory bowel diseases.
[131] S. Hanauer,et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial , 2007, Gut.
[132] M. Martinka,et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. , 2007, Archives of dermatology.
[133] M. Silverberg,et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[134] J. Mary,et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. , 2006, Gastroenterology.
[135] P. Rutgeerts,et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.
[136] P. Rutgeerts,et al. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease , 2005, Current medical research and opinion.
[137] F. Rizzello,et al. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. , 2005, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[138] Samir A. Shah,et al. Smoking and Immunomodulators do not Influence the Response or Duration of Response to Infliximab in Crohn's Disease , 2004, Inflammatory bowel diseases.
[139] M. Bala,et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[140] P. Rutgeerts,et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.
[141] J. Satsangi,et al. An analysis of factors influencing short‐term and sustained response to infliximab treatment for Crohn's disease , 2003, Alimentary pharmacology & therapeutics.
[142] J. Belaiche,et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease , 2002, American Journal of Gastroenterology.
[143] Antonio López-Vázquez,et al. High serum tumor necrosis factor-α levels are associated with lack of response to infliximab in fistulizing Crohn's disease , 2002, American Journal of Gastroenterology.
[144] J. Achkar,et al. Predictors of response to infliximab in patients with Crohn's disease. , 2002, Gastroenterology.
[145] J. Belaiche,et al. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. , 2002, Gastroenterology.
[146] J. Belaiche,et al. A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism , 2002 .
[147] J. Belaiche,et al. Inflammatory Bowel Disease A Positive Response to Infliximab in Crohn Disease: Association with a Higher Systemic Inflammation Before Treatment But Not With -308 TNF Gene Polymorphism , 2002, Scandinavian journal of gastroenterology.
[148] N A Mitchison,et al. The dosage requirements for immunological paralysis by soluble proteins. , 1968, Immunology.
[149] M. Dubinsky,et al. Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD. , 2019, Inflammatory bowel diseases.
[150] B. Flourié,et al. Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[151] P. Rutgeerts,et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. , 2016, The New England journal of medicine.
[152] P. Rutgeerts,et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.
[153] O. Firuzi,et al. Effect of infliximab on the glycosylation of IgG of patients with rheumatoid arthritis , 2007, Journal of clinical laboratory analysis.